3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Carcinoma, Basal Cell
18
Pancreatic Neoplasms
4
Neoplasms
4
Medulloblastoma
3
Stomach Neoplasms
2
Skin Neoplasms
2
Ovarian Neoplasms
2
Glioblastoma
2
Colorectal Neoplasms
2
Basal Cell Nevus Syndrome
2
Urinary Bladder Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Solid Cancers
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Pancreatic Diseases
1
Osteosarcoma
1
Odontogenic Cysts
1
Neurofibrosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Unknown Primary
1
Neoplasms, Basal Cell
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Multiple Myeloma
1
Interventions
Carboplatin
8
Paclitaxel
7
Gemcitabine
7
Irinotecan
6
Radiotherapy
4
Oxaliplatin
4
Capecitabine
4
Leucovorin
3
Fluorouracil
3
Filgrastim
3
Erlotinib Hydrochloride
3
Cisplatin
3
Bevacizumab
3
etoposide phosphate
2
Trastuzumab
2
Surveys and Questionnaires
2
Peripheral Blood Stem Cell Transplantation
2
Etoposide
2
Amifostine
2
Albumin-Bound Paclitaxel
2
tipifarnib
1
tegafur-gimeracil-oteracil
1
sintilimab
1
pertuzumab
1
pemigatinib
1
pembrolizumab
1
olaparib
1
ivosidenib
1
ipatasertib
1
erythromycin propionate-N-acetylcysteinate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplasms, Unknown Primary
×
HhAntag691
×
Clear all
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts